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AbstrACt
background Oncology therapy is becoming increasingly 
more expensive and challenging the affordability and 
sustainability of drug programmes around the world. When 
new drugs are evaluated, health technology assessment 
organisations rely on clinical trials to inform funding 
decisions. However, clinical trials are not able to assess 
overall survival and generalises evidence in a real- world 
setting. As a result, policy makers have little information 
on whether drug funding decisions based on clinical trials 
ultimately yield the outcomes and value for money that 
might be expected.
Objective The Canadian Real- world Evidence for Value 
of Cancer Drugs (CanREValue) collaboration, consisting of 
researchers, recommendation- makers, decision makers, 
payers, patients and caregivers, are developing and testing 
a framework for Canadian provinces to generate and use 
real- world evidence (RWE) for cancer drug funding in a 
consistent and integrated manner.
strategy The CanREValue collaboration has established 
ive formal working groups (WGs) to focus on speciic 
processes in the generation and use of RWE for cancer 
drug funding decisions in Canada. The different RWE WGs 
are: (1) Planning and Drug Selection; (2) Methods; (3) Data; 
(4) Reassessment and Uptake; (5) Engagement. These 
WGs are acting collaboratively to develop a framework 
for RWE evaluation, validate the framework through the 
multiprovince RWE projects and help to integrate the inal 
RWE framework into the Canadian healthcare system.
Outcomes The framework will enable the reassessment 
of cancer drugs, reinement of funding recommendations 
and use of novel funding mechanisms by decision- makers/
payers across Canada to ensure the healthcare system is 
providing clinical beneits and value for money.
bACkgrOund
New therapies for cancer are becoming 
increasingly more expensive, challenging 
the affordability and sustainability of public 
drug programmes in Canada and around 
the world.1–3 While the cost increases of new 
cancer therapies are evident, the benefits 
are not always clear. In the Canadian cancer 
drug funding process, after receiving regula-
tory approval from Health Canada, organi-
sations such as the pan- Canadian Oncology 
Drug Review (pCODR) at the Canadian 
Agency of Drugs and Technologies in Health 
(CADTH) and the Institut national d'excel-
lence en santé et services sociaux (INESSS) 
in Quebec evaluate new cancer drugs and 
make funding recommendations to federal 
and provincial public payers. However, there 
is no policy infrastructure or framework in 
place for postfunding reassessment of cancer 
drugs, leaving payers and policy decision- 
makers with limited opportunity to incor-
porate more mature evidence into funding 
decisions or to renegotiate prices with manu-
facturers based on evolving evidence and 
expanded use.
Traditionally, cancer drug funding deci-
sions have been informed by randomised 
controlled trials (RCTs),4 5 but there can be 
practical and ethical challenges that make 
it difficult to conduct subsequent RCTs.6 7 
Patients in trials can differ significantly from 
patients in practice and the results of RCTs 
can be different from real- world studies,8 9 
limiting the generalisability of RCT evidence 
to a real- world setting.7 10 In recognition of 
these limitations and potential values of real- 
world evidence (RWE), the Canadian Real- 
world Evidence for Value of Cancer Drugs 
(CanREValue) collaboration was established. 
The purpose of this paper is to describe 
the CanREValue collaboration and its work 
toward integrating RWE into cancer drug 
funding decision- making in Canada.
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WhAt is rWE And Why is it nEEdEd?
RWE, generated through the analysis of real- world data 
(RWD), can provide direct and generalisable evidence on 
the comparative effectiveness, safety and cost- effectiveness 
of cancer drugs in clinical practice. RWD is generally 
defined as data collected in a non- RCT setting, and 
includes information typically found in a variety of sources 
such as electronic health records, disease registries and 
administrative databases.11–13 RWE is more prone to data 
bias and confounding than evidence provided through 
an RCT due to lack of randomisation. However, RWE 
has greater external validity by including patients who 
are often not represented in RCTs, such as older adults, 
smokers and patients with comorbidities.14 In addition, 
RWE has the advantage of generating evidence in a less 
expensive manner than RCTs.15
Multiple stakeholders including decision- makers/
payers, health technology assessment (HTA) agencies 
(pCODR/CADTH and INESSS), clinicians and the phar-
maceutical industry have an interest in using RWE. From 
the decision- makers/payers’ perspectives, comparative 
RWE studies of cancer drugs against funded alternatives 
are relevant to policy- making and can be used to support 
system sustainability.11 16 As population- level analyses, 
RWE can provide valuable insights on drugs for rare 
indications. The results of RWE studies can also improve 
payers’ ability to negotiate with industry, including estab-
lishing postmarket commitments and requirements, 
conditional approvals or reimbursement and risk- sharing 
agreements.17 18 Recommendation- makers, such as HTA 
agencies, can also use comparative RWE evidence to reas-
sess their past recommendations and provide updated 
guidance to decision makers/payers.19 The pharmaceu-
tical industry uses RWE across all phases of the drug devel-
opment lifecycle,20 from identification of patients with 
rare diseases to assessment of off- label efficacy.21 RWE 
is also becoming increasingly used to conduct compar-
ative effectiveness studies among treatment options that 
have not been compared directly in RCTs, which can help 
clinicians in their clinical decision- making.22–24
rOlE Of CAnrEVAluE COllAbOrAtiOn
While the potential value of RWE is well established in 
oncology research, technical and methodological chal-
lenges exist in its generation and use by different stake-
holders. For example, the confluence of large datasets 
of uncertain quality, inappropriate data analyses and 
poor research design can produce results that are far 
from mirroring the ‘real world’.25 Moreover, there is no 
consensus on how to incorporate RWE into funding deci-
sions, which limits the use of RWE to inform decision- 
making for payers and decision- makers. The CanREValue 
collaboration aims to address these challenges and estab-
lish a framework for Canadian provinces regarding the 
generation and use of RWE for cancer drug funding deci-
sion making. The development and implementation of 
this framework will result in a process for evidence- based 
reassessment of recommendations on cancer drugs made 
by Canadian HTA organisations and mechanisms for the 
reconsideration of prior funding decisions and/or rene-
gotiations of drug price. Ultimately, these recommenda-
tions, if implemented, will help support health system 
sustainability in Canada and potentially elsewhere.
The CanREValue collaboration was made possible 
through funding from a Partnerships for Health System 
Improvement grant awarded by the Canadian Institutes 
of Health Research and through partnerships with the 
Canadian Centre for Applied Research in Cancer Control 
and Cancer Care Ontario. Key stakeholders in the 
CanREValue collaboration include applied researchers, 
Health Canada, provincial ministries and departments 
of health, HTA organisations, provincial cancer agencies, 
the Canadian Association of Provincial Cancer Agencies, 
the pan- Canadian Pharmaceutical Alliance, the Patented 
Medicine Prices Review Board, clinicians, and patient 
and family representatives (online supplementary table 
S1). Industry is also a key player in the drug funding 
process and will be consulted throughout the framework 
development.
The CanREValue collaboration is a 4- year project. In 
the first year, an environmental scan and qualitative study 
on the use of RWE were conducted. The purpose of the 
environmental scan was to gain an understanding of the 
current state of RWE with respect to healthcare decision- 
making. In the qualitative study, stakeholders were inter-
viewed to gain an understanding of their perspective on 
the development and implementation of a framework for 
the incorporation and use of RWE. The findings of these 
studies will be published separately. In subsequent years, 
the framework will be revised through RWE evaluation 
test cases, additional qualitative interviews and stake-
holder consultations.
CAnrEVAluE WOrking grOups
The CanREValue collaboration has established five formal 
working groups (WGs) to focus on specific processes in 
the generation and use of RWE for cancer drug funding 
decisions in Canada (figure 1). The different RWE WGs 
are: (1) Planning and Drug Selection; (2) Methods; (3) 
Data; (4) Reassessment and Uptake; (5) Engagement 
(see table 1 for a summary of each WG). These WGs act 
collaboratively to develop a working framework; they will 
validate the framework through the multiprovince RWE 
projects, and will help integrate the final RWE framework 
into the Canadian healthcare system. Each WG meets 
to discuss and build consensus, using modified Delphi 
methods,26 27 on issues related to the framework devel-
opment. All WGs meet in- person once a year to share 
updates within and across WGs and to incorporate their 
findings into the overall framework.
rWE planning and drug selection Wg
With the development of an RWE framework, there 
are policy issues that need to be resolved. These include 
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Figure 1 The Canadian Real- world Evidence Value of 
Cancer Drugs project real- world evidence (RWE) working 
groups (WGs) and their roles within the development of the 
framework.
building consensus among payers and decision- makers 
regarding identification criteria of potentially policy- 
relevant RWE evaluations, developing policy infrastructure 
for the RWE study selection process and making recom-
mendations for conducting RWE evaluations. The Planning 
and Drug Selection WG was established to develop criteria 
to identify potential drug indication candidates and select 
high- priority study questions for real- world evaluation. The 
focus of the Planning and Drug Selection WG is on iden-
tifying uncertainties at the time of drug funding that may 
be resolvable through the generation of RWE, along with 
considerations that should be factored into priority- setting 
among a basket of drug candidates. In addition, this WG 
will provide recommendations on potential infrastructure 
for conducting RWE studies.
The Planning and Drug Selection WG consists of 
numerous stakeholders involved in the cancer drug 
funding process including Health Canada, provin-
cial health ministries/departments, provincial cancer 
agencies, HTA organisations, clinicians, patients and 
researchers. A widespread representation of key stake-
holders is important for this WG to ensure that the needs 
and interests of a wide range of potential framework users 
are incorporated. Deliverables for the Planning and Drug 
Selection WG include a set of recommendations for selec-
tion criteria, prioritisation processes and infrastructure 
for RWE evaluations.
rWE data Wg
The CanREValue collaboration will focus on the gener-
ation of RWE using RWD collected from existing 
population- level administrative health databases, such as 
cancer registries, hospital records and insurance claims. 
Unfortunately, administrative healthcare data are often 
collected for routine operations and funding purposes 
and not research purposes. Thus, some elements required 
for research may not be present. Understanding the avail-
ability and usability of the existing data across provinces 
is important to address potential limitations upfront and 
to conduct meaningful RWE studies in the Canadian 
context.
The main tasks of the Data WG are to determine data 
availability and accessibility in each jurisdiction, and 
potential health or economic outcomes that can be 
measured from available data sources, such as survival, 
adverse events, patient- reported outcomes, resource util-
isation and costs. In order to develop a framework that 
is applicable at a pan- Canadian level, there needs to be 
a strategy to identify and harmonise data elements from 
each province. Data experts from all 10 Canadian prov-
inces are working together to explore the current data 
holdings and availability. These data experts will also be 
involved in conducting test case analyses as part of the 
framework development.
The anticipated deliverables for the Data WG are a 
list of strategies that can be used to identify, access and 
harmonise the data elements required to undertake RWE 
projects in each province and a report on provincial data 
availability and accessibility for cancer- specific RWE eval-
uations in Canada.
rWE Methods Wg
The CanREValue collaboration will focus on conducting 
robust comparative observational studies, using clinically 
relevant cancer drugs/regimens currently administered 
in Canada. RWE is often generated from observational 
data, which makes it susceptible to bias that may hinder 
interpretation and use of the findings16 by decision- 
makers and payers.16 28 Therefore, to generate compar-
ative RWE for policy decision- making, appropriate 
analytical approaches need to be selected, with careful 
consideration of issues related to choice of research ques-
tion, study design and research methodology in light 
of available data.29 The goal of the Methods WG is to 
recommend appropriate statistical methods to be used 
to conduct robust RWE evaluations and ensure that the 
findings can provide meaningful information for payers 
and decision- makers.
The Methods WG consists of researchers with expertise 
in HTA, health services research, statistical analysis and 
health economics. The Methods WG will explore a variety 
of analytical strategies and the strengths and the limita-
tions of different methods to address potential bias and 
confounders when estimating key outcomes, including 
safety, effectiveness and cost- effectiveness. The WG will 
then make recommendations on how to apply these 
methods to undertake RWE evaluations with support 
from the Data WG during the test case analyses.
The deliverables for the Methods WG include recom-
mendations on appropriate statistical methods to 
conduct robust RWE evaluations using administrative 
health databases and publications about the conduct of 
RWE evaluations.
rWE reassessment and uptake Wg
There can be uncertainties in the initial HTA of the 
benefits of a new drug due to limitations in the available 
evidence, such as a small sample size or a non- randomised 
study.30 Therefore, there is a need to develop a mechanism 
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Table 1 The summary table for each working group (WG)
Working groups Goals Key issues to address Expected deliverables
Planning and Drug 
Selection WG
To recommend a selection 
process and criteria for 
prioritising RWE evaluations
 Ź Potential markers or signals 
for emerging drugs.
 Ź Policy issue around resource 
allocation and infrastructure 
for conducting RWE 
evaluations.
 Ź Criteria for selecting and 
prioritising RWE evaluation.
 Ź Policy framework for drug 
selection for RWE evaluation.
 Ź Prioritisation process for 
drug selection.
Data WG To identify strategies for data 
access across provinces and 
harmonise data elements 
required for RWE studies
 Ź Determining data availability 
and accessibility of data 
on health or economic 
outcomes.
 Ź Recommendations on 
strategies to identify, 
access and harmonise the 
data elements required to 
undertake RWE projects in 
each province.
 Ź Report on provincial data 
availability and accessibility 
for cancer speciic RWE 
evaluation.
 Ź Conduct RWE evaluations.
Methods WG To recommend statistical 
methods to analyse real world 
data
 Ź Strengths and limitations of 
different analytical strategies.
 Ź Appropriate methods 
for measuring and 
estimating key variables 
(safety, effectiveness and 
cost- effectiveness).
 Ź Recommendations on 
statistical methods to 
conduct RWE evaluations.
 Ź Papers on conducting RWE 
evaluations.
Reassessment and Uptake 
WG
To make recommendation on 
a reassessment process and 
strategies for incorporating 
RWE results into policy 
decisions
 Ź How reassessment will be 
initiated and conducted.
 Ź Funding decision revision.
 Ź Development of policy 
framework for reassessment 
and funding decision.
 Ź Development of 
reassessment process.
 Ź Recommendation on 
strategies for the uptake of 
the RWE framework.
Engagement WG To ensure that all key 
stakeholders are given a 
voice in the development and 
implementation of the RWE 
framework
 Ź Engagement of patient 
groups, clinician groups, 
industry and payers.
 Ź Collect and provide feedback 
from patient groups, clinician 
groups, industry and payers.
RWE, real- world evidence.
to reassess the benefits of some drugs based on evidence 
generated after initial HTA recommendation. This reas-
sessment may allow revised funding decisions and pricing 
discussion based on internationally evolving RWE. The 
purpose of the Reassessment and Uptake WG is to make 
recommendations on a formal reassessment process and 
propose strategies for incorporating RWE findings into 
policy decisions. Building on experience and expertise 
in HTA and policy decision- making, their work will focus 
on developing a reassessment framework to conduct a 
structured, evidence- based critical appraisal of the clin-
ical, social, ethical and economic effects of a technology 
currently used in the healthcare system. This WG will 
develop a process that outlines how reassessment will be 
initiated and by whom, along with how reassessment will 
be conducted, including criteria for reassessment, recom-
mendation outcomes, stakeholders to be involved and 
evidence required to maintain or revise the initial funding 
recommendations. These tasks will increase transparency 
and confidence in reassessment, as well as the utilisation 
of RWE evaluations.
Similar to the Planning and Drug Selection WG, the 
Reassessment and Uptake WG consists of individuals 
from Health Canada, provincial health ministries/depart-
ments, provincial cancer agencies, HTA organisations, 
cancer drug recommendation and decision makers, 
clinicians, patients and researchers. Deliverables for 
the Reassessment and Uptake WG include a systematic 
 o
n
 Septem
ber 10, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032884 on 7 January 2020. Downloaded from 
5Chan K, et al. BMJ Open 2020;10:e032884. doi:10.1136/bmjopen-2019-032884
Open access
process for reassessing cancer drugs that are currently 
funded. In addition, the WG will provide recommenda-
tions to address issues relating to the uptake of the frame-
work including how decision- makers/payers, HTA and 
industry can work together to initiate reassessment and 
renegotiation based on the results of an RWE evaluation.
Engagement Wg
As previously noted, the development and implemen-
tation of the RWE framework requires comprehensive 
collaboration and discussion among the various key stake-
holders. The purpose of the Engagement WG is to ensure 
that all key stakeholders are given a voice in the develop-
ment and implementation of the RWE framework. The 
Engagement WG consists of individuals with perspectives 
from HTA organisations, provincial cancer agencies, 
patients, clinicians and researchers. These individuals 
have a network of connections, expertise and experiences 
in communicating with various stakeholders.
The Engagement WG will focus on developing 
approaches to engage with industry, patient groups, 
clinicians and payers throughout the project. This will 
be an iterative consultation process through formal and 
informal discussion sessions, as well as elicitation and 
incorporation of stakeholder feedback on preliminary 
drafts of reports and recommendations from the other 
WGs. This will ensure that the framework development 
is an inclusive process, which in turn will help to ensure 
that the final framework recommendations are supported 
and adopted.
COnClusiOn
For the successful development and uptake of an RWE 
framework, we recognise that robust evidence should be 
generated through RWE evaluations. At the same time, a 
shared understanding among stakeholders in the cancer 
drug funding landscape needs to be developed and 
agreed on. To this end, the CanREValue collaboration is 
bringing together key stakeholders from across the system 
and country to develop clear guidance, methods and 
processes for how RWE could be generated and used to 
support cancer drug funding decision- making in Canada. 
The diversity of the WG members and their expertise 
ensure that key issues in the generation and use of RWE 
are discussed and recommendations and decisions are 
made using the best evidence possible.
Cancer drug funding decisions are becoming progres-
sively more difficult because of the increasing numbers of 
drugs, their escalating costs,31 and the uncertainty of their 
clinical benefit in the real world.32 The assessment of real- 
world performance of cancer drugs may provide oppor-
tunities to introduce new funding mechanisms such 
as conditional listing, outcomes- based managed entry 
or value- based pricing. RWE evidence may also enable 
the renegotiation of drug prices, which may free up 
funds to allow more drugs to be funded. Ultimately, the 
CanREValue collaboration is working to build consistency 
in the use of RWE at a national level, which will lead to 
a robust pan- Canadian system supporting sustainability, 
value for money and improved patient care.
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